DICE Therapeutics
Dr. Judice currently serves as the co-founder and Chief Executive Officer at DICE Therapeutics. Prior to DICE Therapeutics, Dr. Judice served as Chief Scientific Officer at Cidara Therapeutics, an antifungal company he helped found in 2012. In 2004, Dr. Judice co-founded Achaogen, Inc. (Nasdaq: AKAO), where, as the first employee, he was the Chief Scientific Officer and Chief Executive Officer. During his seven-year tenure at Achaogen, he oversaw three rounds of venture financing, steered its growth to 65 full-time employees and established collaborations with DARPA, NIAID, DTRA and BARDA. Prior to Achaogen, Dr. Judice served as the Vice President of Chemistry at Theravance, where he led the discovery of Vibativ (telavancin).
Dr. Judice received his Ph.D. in organic chemistry from the University of California Los Angeles and did his postdoctoral fellowship at the University of California Berkeley. He received his Bachelor of Science in chemistry from Texas A&M University. Dr. Judice is also a Henry Crown Fellow at the Aspen Institute.
This person is not in any offices
DICE Therapeutics
At DICE Therapeutics, we design and develop innovative therapies in immunology for patients with debilitating disease. Seeking to create a future where convenient oral medicines with biologic-like efficacy are available to patients with serious medical conditions, we are developing oral alternatives to medicines currently limited to injectable forms. We believe that such pills will be widely appreciated by patients and doctors alike, as they provide a lower bar to entry than biologics, and as oral medicines can easily be co-formulated with other efficacious drugs. The combination of our core technology with additional, unique biophysical insights has enabled DICE to target protein-protein interactions with small molecules. In doing so, DICE has cracked open a previously intractable set of clinically validated therapeutic targets, including Interleukin-17 (IL-17). Our lead program – an orally bioavailable IL-17 antagonist for the treatment of psoriasis – is currently progressing through IND-enabling studies. In parallel, we continue to advance both partnered and internal pipeline drug discovery programs, providing a robust pre-clinical pipeline.